This feasibility trial is enrolling 10 participants with chronic spinal cord injury to test the safety of intrathecal Wharton’s jelly mesenchymal stem cell (WJ-MSC) therapy combined with transcutaneous spinal stimulation (tSS). WJ-MSCs are stem cells derived from connective tissue found in the umbilical cord. tSS is a non-invasive technique that uses surface electrodes to deliver electrical stimulation aimed at modifying spinal cord function. If included, participants will receive 3 intrathecal doses of WJ-MSCs at 6-week intervals, combined with 18 weeks of tSS and neurorehabilitation sessions. Final testing of safety and feasibility will be performed after 2 years.
Traumatic
Type
Details
- Participants will receive 3 intrathecal doses of Wharton’s jelly mesenchymal stem cell (WJ-MSC) at 6-week intervals, combined with 18 weeks of transcutaneous spinal stimulation (tSS) assisted neurorehabilitation. - WJ-MSCs are stem cells derived from connective tissue found in the umbilical cord. - tSS is a non-invasive technique that uses surface electrodes to deliver electrical stimulation aimed at modifying spinal cord function. - Final testing of safety and feasibility will be performed after 2 years.
Main benefits
General health
Additional benefits
Arm/hand function
Sensory function
Standing/walking/mobility
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more